Fortrea Holdings Inc. disclosed in an SEC filing today that it received a Civil Investigative Demand from the U.S. Department of Justice. The inquiry concerns data integrity practices in certain clinical trials conducted between 2023 and 2025. Fortrea said it is cooperating fully.
The inquiry has raised investor concerns about potential liabilities and reputational harm to Fortrea as a contract research organization. The company’s stock saw increased volatility in pre-market trading as analysts assessed the probe’s potential financial and operational effects.